|drug3938||modification of the planned therapeutic management Wiki||1.00|
|D010051||Ovarian Neoplasms NIH||1.00|
|D014594||Uterine Neoplasms NIH||1.00|
|D014625||Vaginal Neoplasms NIH||1.00|
|HP:0100650||Vaginal neoplasm HPO||1.00|
|HP:0030416||Vulvar neoplasm HPO||1.00|
|HP:0100615||Ovarian neoplasm HPO||1.00|
There is one clinical trial.
Rapid antigenic tests are not yet used in real life. Their contribution in the diagnostic strategy based on the gold standard including anamnesis, thoracic CT and PCR has not been evaluated. We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.
Description: Comparison of the Gold-Standard PCR, anamnesis, thoracic CT scan versus SARS-Cov-2 antigen, anamnesis and thoracic CT scanMeasure: Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies Time: day 1
Description: Number of diagnoses invalidated by the antigen + CT scan alone without the contribution of PCR.Measure: Positive or negative Covid-19 test Time: day 1
Description: Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19Measure: Positive or negative character of the antibodies test Time: day 1
Description: Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19 at the time of hospitalizationMeasure: Positive or negative character of the antibodies test Time: day 21
Description: Evolution of biological parameters as a function of time IgM IgA and IgGMeasure: Biological parameters Time: day 1
Description: Evolution of biological parameters as a function of time IgM IgA and IgGMeasure: Biological parameters Time: Day 21
Description: medical-economic comparison of the first-line use of the antigenic testMeasure: medical-economic comparison Time: day 1
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports